Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023773 | 0.98 | CNR2 (0.33) | CNR2CNR1 | |
| SCHEMBL22024188 | 0.98 | CNR2 (0.30) | CNR2CNR1 | |
| SCHEMBL20047590 | 0.98 | CNR2 (0.33) | CNR2CNR1 | |
| SCHEMBL18799823 | 0.98 | CNR2 (0.33) | CNR2CNR1 | |
| SCHEMBL21191748 | 0.98 | CNR2 (0.33) | CNR2CNR1 | |
| SCHEMBL24676640 | 0.95 | CNR2 (0.32) | CNR2CNR1 | |
| SCHEMBL21398067 | 0.95 | HDAC8 (0.30) | — | |
| SCHEMBL22964748 | 0.92 | CNR2 (0.32) | CNR2CNR1 | |
| SCHEMBL21191752 | 0.85 | CNR2 (0.38) | CNR2CNR1 | |
| SCHEMBL25627108 | 0.84 | HDAC8 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-11084817-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200102308-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | CNR2 3458/4885CNR1 2568/4885 |
| US-20200102308-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | CNR2 209/4885CNR1 113/4885 |
| US-11084817-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | CNR2 209/4885CNR1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.